Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/CRD.0000000000000337 http://scihub22266oqcxt.onion/10.1097/CRD.0000000000000337 32773440!ä!32773440 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32773440&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Cardiol+Rev 2020 ; 28 (6): 332-334 Nephropedia Template TP {{tp|p=32773440|t=2020. A Review of Remdesivir for COVID-19: Data to Date |pdf=|usr=}}{{32773440}} gab.com Text A Review of Remdesivir for COVID-19: Data to Date JO: Cardiol Rev http://www.kidney.de/pget.php?&tw=1&pmid=32773440 #FOAvip Severe acute respiratory coronavirus-2 (SARS-CoV-2) is responsible for one of the greatest public health challenges of our lifetime, the coronavirus disease 2019 (COVID-19) pandemic. Because of the complicated postinfection sequelae and grave consequences, the search for effective therapies has become a worldwide priority. The antiviral agent remdesivir has become a viable option and is now available in the United States for hospitalized patients through an emergency use authorization. This article describes remdesivir's historical background, pharmacology, key trials, adverse events, and issues regarding accessibility. Twit Text FOAVip A Review of Remdesivir for COVID-19: Data to Date ????Cardiol Rev http://www.kidney.de/pget.php?&tw=1&pmid=32773440 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32773440 #FOAvip English Wikipedia <ref>{{Cite pmid|32773440}}</ref> A Review of Remdesivir for COVID-19: Data to Date #MMPMID32773440 Mehta M; Shyh GI Cardiol Rev 2020[Nov]; 28 (6): 332-334 PMID32773440show ga Severe acute respiratory coronavirus-2 (SARS-CoV-2) is responsible for one of the greatest public health challenges of our lifetime, the coronavirus disease 2019 (COVID-19) pandemic. Because of the complicated postinfection sequelae and grave consequences, the search for effective therapies has become a worldwide priority. The antiviral agent remdesivir has become a viable option and is now available in the United States for hospitalized patients through an emergency use authorization. This article describes remdesivir's historical background, pharmacology, key trials, adverse events, and issues regarding accessibility. |Adenosine Monophosphate/*analogs & derivatives/pharmacology[MESH] |Alanine/*analogs & derivatives/pharmacology[MESH] |Antiviral Agents/pharmacology[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy/virology[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/virology[MESH] |SARS-CoV-2[MESH]A Review of Remdesivir for COVID-19: Data to Date (epmc).pdf DeepDyve Pubget Overpricing